Cargando…

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are extensively used in the treatment of non-small cell lung cancer (NSCLC); hence, equal access to them is important. Therefore, this study aimed to identify regional differences in the prescription of EGFR-TKIs and the factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Hiromi, Kobayashi, Nobuaki, Shinoda, Satoru, Goto, Atsushi, Kaneko, Ayami, Fukuda, Nobuhiko, Kamimaki, Chisato, Kubo, Sousuke, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Ishikawa, Yoshihiro, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063675/ https://www.ncbi.nlm.nih.gov/pubmed/36997606 http://dx.doi.org/10.1038/s41598-023-31856-6

Ejemplares similares

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
por: Kobayashi, Nobuaki, et al.
Publicado: (2021)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer
por: Katakura, Seigo, et al.
Publicado: (2020)

Computed tomography imaging‐based observation of the aggressive growth of angiosarcoma: a case study
por: Kubo, Sousuke, et al.
Publicado: (2019)

Elderly sarcoidosis in Japan
por: Masumoto, Nami, et al.
Publicado: (2022)

Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
por: Teranishi, Shuhei, et al.
Publicado: (2020)

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis
por: Chen, Hao, et al.
Publicado: (2021)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study
por: Fujii, Hiroaki, et al.
Publicado: (2022)

Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Clinical features of asthma with connective tissue diseases
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Inhaled Corticosteroid and Secondary Glaucoma: A Meta-analysis of 18 Studies
por: Ishii, Mai, et al.
Publicado: (2021)

Unusual lung involvements of invasive mucinous adenocarcinoma with chylothorax
por: Aoki, Ayako, et al.
Publicado: (2020)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
por: Chen, Hao, et al.
Publicado: (2020)

The triple therapy for chronic obstructive pulmonary disease increases the risk of pneumonias compared to the dual-bronchodilator therapy
por: Watanabe, Keisuke, et al.
Publicado: (2021)

Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study
por: Hoshi, Miki, et al.
Publicado: (2021)

A functionally improved case of obstructive impairment caused by systemic lupus erythematosus
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Declined Functional Status Prolonged Hospital Stay for Community-Acquired Pneumonia in Seniors
por: Chen, Hao, et al.
Publicado: (2020)

Is rehabilitation effective in preventing decreased functional status after community-acquired pneumonia in elderly patients? Results from a multicentre, retrospective observational study
por: Chen, Hao, et al.
Publicado: (2022)

Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials
por: Ebina-Shibuya, Risa, et al.
Publicado: (2021)

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
por: Kobayashi, Nobuaki, et al.
Publicado: (2023)

Genetic model selection for a case–control study and a meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Fragmentation of ambulatory care among older adults: an exhaustive database study in an ageing city in Japan
por: Kaneko, Makoto, et al.
Publicado: (2022)

An Early Screening Tool for Discharge Planning Shortened Length of Hospital Stay for Elderly Patients with Community-Acquired Pneumonia
por: Chen, Hao, et al.
Publicado: (2021)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy
por: Chen, Hao, et al.
Publicado: (2022)

The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
por: Aoki, Ayako, et al.
Publicado: (2023)

The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease
por: Nishikawa, Yurika, et al.
Publicado: (2021)

Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019
por: Hara, Yu, et al.
Publicado: (2022)

ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease
por: Fujii, Hiroaki, et al.
Publicado: (2023)

Assessment of diagnostic utility of serum hemeoxygenase-1 measurement for acute exacerbation of interstitial pneumonias
por: Kata, Yuki, et al.
Publicado: (2022)

Effect of coexisting advanced extrapulmonary solid cancer on progression of Mycobacterium avium complex lung disease
por: Inoue, Rei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3tbg82b7ag33di40agdgruknje